Alzheimer's disease, a severe neurodegenerative disorder, is believed to be caused by the interneuronal aggregation of the amyloid β peptide. It has no cure yet. Despite rigorous research, the mechanism of aggregation is not yet fully delineated. Especially probing the early events of the aggregation is difficult as we have no control on the kinetics of the process of aggregation. We have used amyloid β derived switch-peptides that behave as the functional mimic of the amyloid β peptide, and demonstrated that side chain aromatic interactions precede the β-sheet formation resulting in fibrillization. Detailed investigation into the early events of aggregation has become possible as the kinetics of aggregation of the switch-peptides can be controlled. We have used ultraviolet (UV) spectroscopy, circular dichroism (CD), Raman spectroscopy and Molecular Dynamics (MD) simulation as a combined experimental and theoretical approach.
Scheduled maintenance upgrade on Saturday 2nd of July 2016 from 11.30am to 3.00pm (BST)
During this time our websites will be offline temporarily. If you have any questions please use the feedback button on this page. We apologise for any inconvenience this might cause and thank you for your patience.
Research and review articles in medicinal chemistry and related drug discovery science; the official journal of the European Federation for Medicinal Chemistry
Impact Factor
2.319
12 Issues per Year
Research Article
Amyloid β derived switch-peptides as a tool for investigation of early events of aggregation: a combined experimental and theoretical approach
Med. Chem. Commun., 2016,7, 311-316
DOI: 10.1039/C5MD00466G
Received 13 Oct 2015, Accepted 25 Nov 2015
First published online 01 Dec 2015
Please choose one of the options provided in the log in section to gain access to
this content:
MedChemComm
- Information Point
Log in
Supplementary Info
-
Supplementary information
PDF (979K)